July 20, 2018

Brian Hill, MD, PhD, and Mikkael Sekeres, MD, MS, Chair State of the Science Summit

OncLive summit on hematologic malignancies Oct. 4

nci-vol-2335-72_650x450

On Oct. 4, Brian Hill, MD, PhD, Director of the Lymphoma Program, and Mikkael Sekeres, MD, MS, Director of the Leukemia Program and Vice Chair for Clinical Research, will chair one of OncLive’s State of the Science Summits being held this year in cities across the U.S. The overall program will cover important advances in the treatment of hematologic malignancies including mantle cell lymphomamultiple myelomachronic lymphocytic leukemia (CLL) and more. The Summits help community oncologists in diverse specialties stay current on the latest evidence-based treatment strategies for their patients.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Dr. Hill will discuss CLL. He is an expert in lymphoid malignancies. “This session will help participants get up-to-date on some of the newest developments in the management of hematologic malignancies,” says Dr. Hill.

Dr. Sekeres, an expert in myeloid malignancies, will discuss myelodysplastic syndromes. “This meeting will provide ‘boots on the ground’ guidance for managing these complicated cancers in an era of expanding treatment choices,” says Dr. Sekeres.

Each of the State of the Science Summits brings together academic and community-based physicians and healthcare professionals across key disciplines from medical and surgical oncology.

Advertisement

Other Cleveland Clinic presenters include Hetty Carraway, MDRobert Dean, MD, and Aaron Gerds, MD, and Jason Valent, MD, staff in the Department of Hematology and Medical Oncology. The meeting will take place on Thursday, Oct. 4, from 5-9 pm at Metropolitan at the 9 hotel in Cleveland.

Visit onclive.com/meetings/soss to register.

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad